MannKind | MNKD - Cost Of Sales


MannKind reported $33.65M in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
Adma Biologics USD 50.4M 8.24M Dec/2025
BioCryst Pharmaceuticals USD 9.52M 7.34M Dec/2025
Eli Lilly USD 3.37B 363.7M Dec/2025
Halozyme Therapeutics USD 102.15M 29.14M Dec/2025
Insmed USD 46.16M 15.25M Dec/2025
Karyopharm Therapeutics USD 1.48M 35.95M Dec/2025
MacroGenics USD 10.12M 34.18M Dec/2025
MannKind USD 33.65M 13.44M Dec/2025
Merck USD 3.32B 531M Dec/2025
Minerva Neurosciences 386K 31K Jun/2024
Novavax USD 22.1M 608K Dec/2025
Novo Nordisk DKK 1.95B 10.94B Jun/2025
Pfizer USD 6.29B 2.12B Dec/2025
Sanofi EUR 4.29B 421M Dec/2025
Xencor USD 61.66M 50.95M Jun/2025